Zafgen, Inc. (ZFGN) Stock Rating Lowered by Zacks Investment Research
Zafgen, Inc. (NASDAQ:ZFGN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Friday.
According to Zacks, “Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts. “
Separately, ValuEngine raised shares of Zafgen from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 6th. One research analyst has rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company. Zafgen currently has a consensus rating of “Hold” and a consensus target price of $6.38.
Shares of Zafgen (NASDAQ ZFGN) opened at 3.37 on Friday. The stock’s market cap is $92.62 million. The firm has a 50 day moving average of $3.45 and a 200 day moving average of $3.98. Zafgen has a one year low of $2.89 and a one year high of $5.46.
Zafgen (NASDAQ:ZFGN) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.52) by $0.03. During the same quarter last year, the firm posted ($0.55) earnings per share. On average, equities research analysts predict that Zafgen will post ($2.23) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/09/17/zafgen-inc-zfgn-stock-rating-lowered-by-zacks-investment-research.html.
In other news, insider Dennis D. Kim bought 10,000 shares of the firm’s stock in a transaction on Tuesday, July 11th. The stock was bought at an average cost of $3.39 per share, for a total transaction of $33,900.00. Following the completion of the acquisition, the insider now directly owns 21,443 shares in the company, valued at approximately $72,691.77. The purchase was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 21.20% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in ZFGN. Algert Global LLC acquired a new position in shares of Zafgen in the second quarter worth about $123,000. Parametric Portfolio Associates LLC boosted its holdings in shares of Zafgen by 55.8% in the first quarter. Parametric Portfolio Associates LLC now owns 28,832 shares of the biopharmaceutical company’s stock worth $134,000 after buying an additional 10,327 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of Zafgen by 1,290.3% in the first quarter. Wells Fargo & Company MN now owns 43,531 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 40,400 shares during the period. GSA Capital Partners LLP acquired a new position in shares of Zafgen in the second quarter worth about $259,000. Finally, LMR Partners LLP acquired a new position in shares of Zafgen in the second quarter worth about $299,000. Institutional investors own 48.52% of the company’s stock.
Zafgen Company Profile
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
Receive News & Stock Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related stocks with our FREE daily email newsletter.